Methods and systems for information exchange of a vehicle in a networked multiagent system are disclosed. The methods and systems include: receiving a last neighbor dataset broadcasted by a neighbor vehicle; determining a current dataset based on the last neighbor dataset and a last vehicle dataset of the first vehicle; identifying a violation of an event-triggering condition by comparing a difference between the last vehicle dataset and the current dataset with a dynamic threshold; determining a transmission dataset being associated with the current dataset; and in response to the violation, broadcasting the transmission dataset to the neighbor vehicle. The dynamic threshold is defined by an exponentially decaying term and an error between a vehicle state of the first vehicle and a reference state. Other aspects, embodiments, and features are also claimed and described.
G08G 1/01 - Detecting movement of traffic to be counted or controlled
H04L 67/12 - Protocols specially adapted for proprietary or special-purpose networking environments, e.g. medical networks, sensor networks, networks in vehicles or remote metering networks
2.
DETERMINING ELECTRONIC COMPONENT AUTHENTICITY VIA ELECTRONIC SIGNAL SIGNATURE MEASUREMENT
Examples of determining electronic component authenticity via electronic signal signature measurement are discussed. Reference pin identifiers corresponding to pins of a known authentic electronic component are determined. Measurement values corresponding to characteristics of pins of an electronic component are obtained, and pin identifiers based on the measurement values are generated. Accordingly, an indication that the electronic component is authentic can be provided based at least in part on a comparison of the pin identifiers and the reference pin identifiers.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/4706 - 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
A method for achieving a target joint preload can include applying a tightening torque to the second fastener element and measuring that torque as a trial tightening torque. The method can further include applying a loosening torque to the second fastener element and measuring that torque as a trial removal torque. Additionally, the method can include calculating a required tightening torque that is required to be applied to the second fastener element to achieve the target joint preload using only the thread pitch, the trial tightening torque, the trial removal torque, and the target joint preload.
B25B 23/147 - Arrangement of torque limiters or torque indicators in wrenches or screwdrivers specially adapted for electrically operated wrenches or screwdrivers
G01L 5/24 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes for determining value of torque or twisting moment for tightening a nut or other member which is similarly stressed
A dispensing system can include a container including multiple channels, and each channel can be capable of containing an amount of a liquid. The dispensing system can include a well plate including multiple wells, and each well can be configured to align with a respective channel of the container. The dispensing system can include a plunger including multiple protrusions, and each protrusion can be configured to be inserted into a respective channel of the container. Movement of the plunger toward the container can force each protrusion to be inserted into the respective channel of the container thereby driving liquid from the respective channel and into a respective well of the well plate.
Compositions and methods of treatment for inhibiting capillary tube regression and/or lymphatic tube regression are described, as well as factors and signaling pathways that control the regression of capillary tube networks. Capillary tube regression and/or lymphatic tube regression may be implicated in ischemia, infarction, hypertension, diabetes, malignant cancer, neurodegenerative disease, wound repair response, atherosclerosis, pro-inflammatory disease, pro-thrombotic disease, viral infection (e.g., influenza or SARS-CoV-2), bacterial infection.
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4418 - Non-condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
7.
Microparticle compositions for controlled delivery of telmisartan and actinomycin D
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS (USA)
Inventor
Mohapatra, Subhra
Mohapatra, Shyam S.
Markoutsa, Eleni
Gonzalez, Alejandro J.
Jadhav, Heta N.
Abstract
This disclosure is directed to therapeutic compositions, and more particularly to microparticle compositions for the controlled delivery of telmisartan and actinomycin D.
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 47/08 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A composition, workout/exercise supplement, treatment method for conditions associated with vasoconstriction, and method of extracting galloylated procyanidins. The composition includes galloylated procyanidins having a preponderance of (−)-epicatechins. The treatment methods include administering a therapeutically effective amount of galloylated procyanidins having a preponderance of (−)-epicatechins. The extraction methods include isolating galloylated procyanidins having a preponderance of (−)-epicatechins from a sample that contains polyphenols, catechins, epicatechins, and galloylated epicatechins.
A method of data encryption for messages transmitted between two or more computing devices includes determining a current secret key that is shared between a first computing device and a second computing device, calculating a current message authentication code (MAC) based on the current secret key and the message, calculating a subsequent secret key based on the current secret key using a one-way pseudorandom function, calculating a subsequent MAC by aggregating the current MAC and a first preceding aggregate MAC, and encrypting the message using the subsequent MAC and the subsequent secret key.
H04L 9/32 - Arrangements for secret or secure communications; Network security protocols including means for verifying the identity or authority of a user of the system
10.
FUNCTIONALIZED POROUS ORGANIC POLYMERS AS URANIUM NANO-TRAPS FOR EFFICIENT URANIUM EXTRACTION
Compositions are provided for efficient uranium extraction, for example from wastewater, seawater, or other water sources. The compositions can include a functionalized porous organic polymer functionalized with one or more uranium binding moieties, e.g. having a plurality of amidoxime or amidrazone groups covalently attached thereto. The compositions can include covalent organic frameworks, porous aromatic frameworks, and various porous organic polymers, especially those having a hierarchical pore size distribution over a range of pore sizes. The compositions can have functional groups such as amidoxime or an amidrazone covalently attached thereto. The hierarchical pore size distribution can be determined based upon at least 60% of the pore sizes in the range of pore sizes having a pore volume of at least 0.01 cm3 g−1 in the pore size distribution at 77 K. Methods of making the compositions and methods of using the compositions are also provided.
B01J 20/28 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B01J 20/30 - Processes for preparing, regenerating or reactivating
C08F 112/34 - Monomers containing two or more unsaturated aliphatic radicals
Disclosed herein is a solar thermal osmosis desalination system comprising a forward osmosis subsystem and a reverse osmosis subsystem where the forward osmosis subsystem is configured to receive solar thermal heat and generate power that can be used to operate the reverse osmosis subsystem.
A nanosystem and methods of treating, including prophylactically, coronavirus infections, such as those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by administering such nanosystem to a patient is presented. The nanosystem may be comprised of a single or a combination of therapeutic agents, optionally encapsulated in a nanoparticle having a targeting moiety directed to the particular coronavirus. For CoV-2 infections, at least one therapeutic agent, such as the dual DPP4/ACE2 inhibitor sitagliptin, may optionally be encapsulated within a nanoparticle having a fatty acid such as linoleic acid, as the targeting moiety. Administration can occur intranasally prior to infection for prophylactic treatment or post-infection for treatment of the viral infection.
Provided herein are systems and methods for sampling analytes into an atmospheric pressure inlet mass spectrometer using ultrasonic nebulization-assisted atmospheric pressure chemical ionization. The systems can include a mass spectrometer having an input and an ultrasonic nebulizer chip. The ultrasonic nebulizer chip can be operatively coupled to the mass spectrometer, such that when the ultrasonic nebulizer chip nebulizes the analyte to provide a nebulized analyte, at least some of the nebulized analyte enters the input of the mass spectrometer.
H01J 49/00 - Particle spectrometers or separator tubes
H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components
H01J 49/24 - Vacuum systems, e.g. maintaining desired pressures
14.
SYSTEM AND METHOD OF FINE-TUNING LARGE LANGUAGE MODELS USING DIFFERENTIAL PRIVACY
A system and method of fine-tuning a large language model including differential privacy includes pretraining a large language model using a non-private dataset to generate a pretrained output. The pretrained output is used as an input to a fine-tuning model. The pretrained output is fine-tuned using a private dataset to generate a differentially private large language model. A set of privacy parameters including a privacy budget and a failure probability are determined. A privacy analysis agent calculates a desired amount of privacy based on the privacy budget, and calculates a noise multiplier based on the desired amount of privacy. The pretrained model is transformed using the noise multiplier to add an amount of noise to the pretrained output. A randomized differentially private stochastic gradient descent model fine-tunes the transformed pretrained output by reparametrizing a weight matrix associated with each layer of the transformed pretrained output.
The present disclosure relates to methods of determining complementarity scores of antigen-binding proteins and proteins associated with cancers and uses thereof for diagnosing and treating cancers and for screening antigens and antigen-binding proteins.
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
16.
SYNTHETIC PLASMODIUM ANTIGENS, COMPOSITIONS, AND USES THEREOF
Provided herein are synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof. Also provided herein are methods of treating and/or preventing Plasmodium infection and/or disease by administering the synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof.
The present disclosure provides for a photocrosslinkable tissue bonding composition comprising: a poly(ethylene glycol) functionalized with at least one photocrosslinkable group, a hydroxy-modified chitosan, and a photochemically active dye. Further provided herein is a photocrosslinked tissue bonding composition comprising: a photochemically active dye and a functionalized poly(ethylene glycol). Also disclosed is a kit for treating a wound, comprising a poly(ethylene glycol) functionalized with at least one photocrosslinkable group, a hydroxy-modified chitosan, a photochemically active dye, and an applicator. Further provided is a method for producing a photocrosslinkable tissue bonding composition and a method for treating a wound.
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61P 15/06 - Antiabortive agents; Labour repressants
19.
STRATEGY TO INCREASE ANTI-VIRAL, ANTI-MICROBIAL, AND ANTI-FUNGAL DEFENSE
Disclosed herein are compositions and methods for inducing, promoting, or enhancing an immune response in a subject. For example, the disclosed compositions and methods can be used prophylactically to prevent viral/microbial infections or therapeutically to treat acute infections. In some embodiments, the disclosed method involves administering to the subject a composition comprising in vitro transcribed (IVT) RNA comprising short interspersed nuclear elements (SINEs), such as Alu repeats. In some embodiments, the disclosed compositions and methods can be used to induce, promote, or enhance any immune response in a subject, including an anti-viral, anti-microbial, anti-fungal, or anti-parasite response. In some embodiments, the disclosed compositions can be administered to any mucosal barrier, such as lungs or intestines, e.g. to enhance an innate immune response against a virus or pathogen.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Disclosed are devices and methods for synthesizing products. The disclosed devices and methods may be used to synthesize products, e.g., pharmaceutical or therapeutic compounds (i.e., drugs), ceramics, catalysts, biological polymers (i.e., proteins, enzymes), cells, tissues, or combinations thereof. The devices and methods may be operated in a microgravity environment.
B01F 35/52 - Receptacles with two or more compartments
B01F 27/83 - Mixers with rotary stirring devices in fixed receptacles; Kneaders with stirrers rotating about a substantially vertical axis the stirrers being additionally moved radially, or oscillating about an axis perpendicular to the stirrer axis
B01F 35/00 - Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
Disclosed herein are electrotransfer (ET) methods for delivering therapeutic agents to tumors. Also disclosed are methods of using the ET methods for differential delivery of an agent to more than one tissue. For example, the ET methods can be used to deliver soluble peptides of PD1 to tumor tissue to block normal PD1-PDL1 binding while separately using the ET methods to deliver PD1 or PDL1 antigen to another tissue, such as skin or muscle, to induce systemic and polyclonal checkpoint inhibitor antibodies.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Farese, Robert Vito
Sajan, Mini Paliyath
Higgs, Margaret Genevieve
Abstract
Provided herein are formulations effective for and methods of treating or preventing a neurodegenerative disorder in a subject in need thereof that can include administering an amount of an aPKC inhibitor to a subject in need thereof.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
23.
AUTONOMOUS CONTROL USING HIERARCHICAL ENSEMBLES OF AUTONOMOUS DECISION SYSTEMS
A Hierarchical Ensembles of Autonomous Decision Systems (HEADS) system with a recursive ensemble weighting update is proposed. The system is built on fuzzy logic leading to an understandable and tractable logic design that leverages subject matter experts to design system operations. The hierarchical structure enables multi-layered logic for granular control and decisions incorporating inferred information. The control output from each ensemble is a mixture from independently trained fuzzy systems processed through a gating network. The gating network weights are updated recursively. Each expert uses a subset of the input space to minimize per-expert complexity and support ensemble robustness under uncertain or evolving state realizations and operating environments. Finally, autonomy based on fuzzy systems offers the potential for increased human comprehension of an agent's status and decision logic.
Image denoising systems and methods to provide light-weight, high quality, and individually denoised images, which facilitate quick and accurate medical diagnosis from medical images. The systems and methods include: obtaining a medical image of a subject; determining a set of noisy patches from the medical image; determine a dictionary based upon the set of noisy patches by learning a sparse representation of the medical image; denoise the set of noisy patches to create a set of denoised patches; denoise the medical image by reconstructing the denoised set of patches into a denoised version of the medical image; and present the denoised version of the medical image for viewing by a user.
A multi-functional broad-spectrum antiviral and anti-inflammatory nanosystem and methods of treating, including prophylactically, coronavirus infections, such as those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by administering such nanosystem to a patient is presented. The nanosystem may be comprised of a combination of therapeutic agents directed to the particular coronavirus encapsulated in a nanoparticle that is surface coated with a targeting moiety. For CoV-2 infections, an antiviral such as the PPAR-γ agonist leriglitazone (LG) and an siRNA targeting a conserved sequence of the virus can be encapsulated within a nanoparticle surface coated with a fatty acid such as linoleic acid, as the targeting moiety. Administration can occur intranasally prior to infection for prophylactic treatment or post-infection for treatment of the viral infection.
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Methods and systems for control of multiagent networks with misbehaving vehicles over directed network topologies are disclosed. The methods and systems include: identifying a plurality of possible misbehaving vehicles among a plurality of vehicles in the networked multiagent system, determining a directed sub-network of a subset of the plurality of vehicles based on a first directed communication path of a first possible misbehaving vehicle of the plurality of possible misbehaving vehicles to a first vehicle and a second directed communication path of a driver vehicle of the plurality of vehicles to the first vehicle; and implementing a proportional-integral controller for suppressing an effect of the misbehaving vehicle on the networked multiagent system. Other aspects, embodiments, and features are also claimed and described.
In one embodiment, an electrochromic device includes a single active layer configured to be alternately placed in a light-transmitting state in which relatively large amounts of light can be transmitted through the active layer and a light-blocking state in which relatively small amounts of light can be transmitted through the active layer, where the device comprises no other layers of material that contribute to transitioning between the two states
G02F 1/1516 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect characterised by the electrochromic material, e.g. by the electrodeposited material comprising organic material
Structures of a particle containing a core and at least one shell, a metal oxide material of which is necessarily doped to ensure protection of a material of the core from photodegradation. The core can include any of a thermochromic material, a phase-change material, and a judiciously defined auxiliary material that in turn contains organic and/or polymeric material. Derivative products utilizing a plurality of such particles. Methodologies for producing such particles and derivative products.
B01J 13/06 - Making microcapsules or microballoons by phase separation
B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing electromagnetic waves
C04B 14/36 - Inorganic materials not provided for in groups
C04B 16/00 - Use of organic materials as fillers, e.g. pigments, for mortars, concrete or artificial stone; Treatment of organic materials specially adapted to enhance their filling properties in mortars, concrete or artificial stone
A novel composition and method of enhancing wound healing and minimizing rejection of an implant is presented. The composition is a dry acellular mixture comprised of conditioned media from mesenchymal stem cells, a multifunctional protease inhibitor, and a tethering peptide that acts as a tether to keep the composition in contact with the targeted area. An antimicrobial fusion peptide may also be added to the composition.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (USA)
UNIVERSITY OF SOUTH FLORIDA (USA)
Inventor
Hall, Maclean
Abate-Daga, Daniel
Abstract
Disclosed are novel adoptive cell therapies comprising engineered CD4+ T cells comprising novel T cell receptors and methods of their use in the treatment of cancer.
The United States Government as represented by the Department of Veterans Affairs (USA)
Inventor
Kearns, William Diehl
Crosland, Kimberly Ann
Craighead, Jeffrey D.
Fozard, James Leonard
Abstract
A medication adherence system and corresponding medication box for improving medication adherence. The system includes the medication box, which is transparent and has a machine-readable marker, such as a QR code, on or beneath the floor thereof. The marker is capable of being scanned and read through the transparent bottoms of individual chambers. Data embedded in the marker includes, but is not limited to, the user's medication plan, the date and time when the medication is to be ingested, and instructions for recording the date and time when the marker is scanned and read. The underlying software program/application processes this information and provides an indication as to the user's compliance with the medication plan.
A61J 7/04 - Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
A61J 7/00 - Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
G06K 19/06 - Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
32.
ATTENTIONAL GENERATIVE MULTIMODAL NETWORK FOR PAIN ESTIMATION
Methods and systems for pain assessment are disclosed. The methods and systems include: obtaining a trained first, second, and third artificial intelligence (AI) models; obtaining sensor data for each modality of multiple modalities for a sequence length; determining a latent feature space in the sequence length for each modality of the multiple modalities based on the first AI model and the sensor data for each modality; generating a common latent space based on the second AI model and the latent feature space of each modality of the multiple modalities; generating a reconstructed latent space for each modality of the multiple modalities based on the common latent space and the second AI model; and determining a pain indication and/or a level of intensity based on the third AI model. Other aspects, embodiments, and features are also claimed and described.
G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
33.
NOVEL CYCLIC GAMMA AAPEPTIDE PAN-CORONAVIRUS INHIBITOR AND METHOD OF TREATING CORONAVIRUS INFECTION
A novel compound and method of treating and preventing coronavirus infection in a patient is presented. Cyclic γ AApeptide pan-coronavirus inhibitors which bind to RBD and HR1 on the spike protein were found to exhibit high proteolytic enzyme stability and good oral bioavailability. In particular, compound S-20-1 effectively inhibited infection by pseudotyped and authentic SARS-CoV-2 and pseudotyped variants of concern (VOCs), including B.1.617.2 (Delta) and B.1.529 (Omicron), as well as MERS-CoV, SARS-CoV, HCoV-OC43, HCoV-229E, and HCoV-NL63 as well as infection of a pseudotyped SARS-related coronavirus WIV1 (SARSr-CoV-WIV1) from bats.
Disclosed herein are compounds that can prevent and treat C. difficile by inhibiting sporulation. Also disclosed herein are compositions and formulations comprising the compound disclosed herein. Methods of preventing and treating C. difficile comprising administering the compounds described herein are also disclosed.
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (USA)
UNIVERSITY OF SOUTH FLORIDA (USA)
Inventor
Mclaughlin, Mark
Morse, David L.
Pilon-Thomas, Shari
Antonia, Scott
Abstract
The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
This disclosure relates to antimicrobial compositions, and more particularly to treatment of surfaces (e.g., face masks) for the reduction or prevention of transmission of microbes (e.g., bacteria, fungus, and/or viruses). In some embodiments, the compositions comprise a cationic polymer selected from the group consisting of: a polydiallyldimethylammonium salt, a polyethyleneimine salt, a polydiallyldimethylammonium with different counter ions, a chemically modified polyethyleneimine salt, or a combination thereof.
Hybrid particles having improved electrical conductivity and thermal and chemical stabilities are disclosed. The hybrid particles are for use in conductive pastes. The hybrid particles include a nanoparticle selected from a graphene-containing material, a dichalcogenide material, a conducting polymer, or a combination thereof encapsulated in a conducting metal. The hybrid particles include a nanoparticle selected from a graphene-containing material, a dichalcogenide material, or a combination thereof encapsulated in a conducting polymer, and optionally further in a conducting metal. Suitable conducting metals include nickel or silver. Suitable conducting polymers include polyaniline, polypyrrole, or polythiophene. Suitable dichalcogenide materials include MoS2 or MoSe2. The hybrid particles can further include a conducting polymer layer on an outer surface of the conducting metal. Methods of making the hybrid particles are also disclosed.
H01B 1/02 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of metals or alloys
H01B 1/12 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of other non-metallic substances organic substances
38.
SYSTEMS AND METHODS TO OPTIMIZE AND FRACTIONIZE RADIATION FOR PERSONALIZED RADIATION THERAPY
H. Lee Moffitt Cancer Center and Research Institute, Inc. (USA)
University of South Florida (USA)
Inventor
Torres-Roca, Javier
Peacock, Jeffrey
Liu, Xiaoming
Abstract
Systems and methods for personalized dose and fractionation for radiation therapy are described herein. An example method can include predicting a patient-specific radiosensitivity parameter alpha (α) value for a tumor, where the patient-specific radiosensitivity parameter alpha (α) value is predicted based on a first set of signature genes. The method can also include predicting a patient-specific radiosensitivity parameter beta (β) value for the tumor, where the patient-specific radiosensitivity parameter beta (β) value is predicted based on a second set of signature genes. The method can further include calculating a patient-specific dose and fractionation using a radiation cytotoxicity score (RCS) function and the patient-specific radiosensitivity parameters alpha (α) and beta (β) values. RCS is predictive of clinical outcome.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 25/00 - ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
Various examples are provided for systems and methods for geodesy in shallow water. In one example, a method includes obtaining, from a sensor module, a position of a superstructure of a moored device. At least one measurement corresponding to a heading, a pitch, or a roll of the superstructure can be obtained from the sensor module. An estimated position of an anchor, ballast, or other seafloor marker of the moored device can be determined based on the position of the superstructure and at least one corrected heading associated with the at least one measurement. The at least one corrected heading can be determined by applying a magnetic declination correction to the at least one measurement.
Systems and methods for processing a service request within a network environment can include a first cluster of fog nodes that execute service tasks. The cluster can include a primary fog node and nearest neighbor fog nodes. The primary fog node can receive, from the network, a service request, determine service request resource data that includes a first time, quantity of resource blocks required to serve the request, and a hold time required to serve the request locally. An edge controller, connected to the network and the first cluster, can receive, from the primary fog node, the service request resource data, identify available resources at the nearest neighbor fog nodes and the primary fog node, and determine whether resource blocks are available to fulfill the service request using deep reinforcement learning algorithms. The edge controller can also refer a rejected service request to a cloud computing system for execution.
H04L 41/083 - Configuration setting characterised by the purposes of a change of settings, e.g. optimising configuration for enhancing reliability for increasing network speed
H04L 41/16 - Arrangements for maintenance, administration or management of data switching networks, e.g. of packet switching networks using machine learning or artificial intelligence
41.
4D-perfused tumoroid-on-a-chip platform for personalized cancer treatment applications
A 4D-perfused tumoroid-on-a-chip platform used in personalized cancer treatment. The platform includes a plate with a plurality of bottomless wells that resides atop a microfluidic channel layer, which in turn resides atop a surface acoustic wave (SAW) based sensor layer that is capable of measuring potential pH values of fluids disposed within the platform. The microfluidic channel layer includes a plurality of bioreactors, with each bioreactor including an inlet well, a culture well, and an outlet well. The inlet well, culture well, and outlet well form a closed system via fluid conduits spanning from the inlet well to the culture well, as well as from the culture well to the outlet well. Due to the fluid flow from the plate to the chip, and from the inlet well to the outlet well on the chip through the culture well, target cell (tumoroid) growth is promoted within the culture well.
The present disclosure provides an electrode device and methods of making and using the same. The electrode device includes a base layer, an intermediate layer, and a capping layer. Both the intermediate layer and the capping layer are located over the base layer. The intermediate layer includes a carbon-based electrode. The base layer and the capping layer each include silicon carbide. The capping layer partially surrounds the carbon-based electrode. The method of using the electrode device as an implantable neural interface involves providing the electrode device, electrically coupling the carbon-based electrode to neural tissue of a patient, and electrically coupling the carbon-based electrode to at least one of recording electronics and stimulating electronics. The recording electronics are configured to electrically record neural signals from the neural tissue, whereas the stimulating electronics are configured to electrically stimulate the neural tissue.
An energy harvesting roadway that includes a plurality of road segments and a power storage device electrically coupled to the plurality of road segments. Each of the plurality of road segments can include a surface asphalt layer, a first conductive asphalt layer located under the surface asphalt layer, a piezoelectric-based asphalt layer located between the first conductive layer and a second conductive layer located above a base asphalt layer. The piezoelectric-based asphalt layer can include a plurality of rigid piezoelectric elements and an insulating filler.
E01C 1/00 - Design or layout of roads, e.g. for noise abatement, for gas absorption
H02N 2/18 - Electric machines in general using piezoelectric effect, electrostriction or magnetostriction producing electrical output from mechanical input, e.g. generators
44.
METHODS AND SYSTEMS FOR DETERMINING AN IONIC STRENGTH OF A DILUTE AQUEOUS SOLUTION
Disclosed herein are methods for measuring the ionic strengths of the natural water sources. Also disclosed herein are systems used to measure an ionic strength of the natural water sources. More specifically disclosed herein are methods and systems utilizing spectroscopic pH measurements and calculations of the ionic strength as a function of the measured pH.
A method of modulating neural activity using a combination of electrical and optical stimulation transmitted via a gold nanoparticle covered nanoelectrode is presented. The combination of short-duration green visible light optical pulses with the complementary sub-threshold level electric current pulses are capable of producing action potentials in neurons. Cells were found to have a greater than a 5× survival rate using this hybrid stimulation method as compared to pure plasmonic/optical stimulation. The cell stimulation success rate was 3× greater with hybrid stimulation.
A soft ferrite composition comprises a ferrimagnetic ceramic material having a crystal structure and a dopant in the crystal structure, wherein the ceramic material comprises an oxide including nickel, cobalt, zinc, and iron, wherein the dopant is selected from the group consisting of copper oxides, and wherein the dopant is present in the crystal structure at 0.1 to 20 weight percent based Non a total weight of the composition. The dopant can be CuO. The copper oxide doped Ni—Co—Zn ferrite can be used for very high frequency (VHF) and ultra high frequency (UHF) applications such antennas, isolators, and circulators.
C04B 35/26 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on ferrites
H01F 1/34 - Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials non-metallic substances, e.g. ferrites
Systems and methods for multiple object transferring using robotics. A system includes a robotic hand with a base and fingers capable of grasping objects. A robotic arm is coupled to the robotic hand and is capable of moving the robotic hand. One or more circuits are configured to operate the robotic hand and the robotic arm by identifying a pre-grasp configuration for the robotic hand and executing a transfer routine based on a Markov decision process model to operate the robotic hand and the robotic arm such that they move multiple objects from a first location to a second location.
Membranes comprising chitosan and re-acetylated chitosan for use in desalination and Salinity Gradient Power Vapor Pressure Desalination (SGP-VPD). A thin film composite (TFC) membrane comprising a minimally hydrophilic re-acetylated chitosan outer layer and a substantially hydrophilic chitosan porous support layer for performing desalination and a multi-layer membrane comprising substantially hydrophobic re-acetylated chitosan inner and outer layers surrounding a substantially hydrophilic chitosan porous support layer for performing SGP-VPD.
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 33/00 - Medicinal preparations containing inorganic active ingredients
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Methods and systems for macroalgae or marine debris detection are disclosed. A method includes accessing or receiving multispectral aerial images of a target region; preprocessing the aerial images; determining, using one or more characteristics of the aerial images, an image type for each of the aerial images; generating the one or more geospatial data images by: providing preprocessed aerial images of each image type to a machine learning algorithm trained using images having that image type; receiving, as outputs from each DCNN, image data indicating whether macroalgae are present in regions corresponding to each pixel of the aerial images; altering pixel values of the aerial images to visually indicate the presence of macroalgae in regions corresponding to the altered pixel values; and providing the one or more geospatial data images to the user device via a user interface. Other aspects, embodiments, and features are also claimed and described.
G06V 10/58 - Extraction of image or video features relating to hyperspectral data
G06V 10/774 - Generating sets of training patterns; Bootstrap methods, e.g. bagging or boosting
G06V 10/26 - Segmentation of patterns in the image field; Cutting or merging of image elements to establish the pattern region, e.g. clustering-based techniques; Detection of occlusion
G06V 10/60 - Extraction of image or video features relating to illumination properties, e.g. using a reflectance or lighting model
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
51.
SYSTEM AND METHOD FOR CRYPTOGRAPHIC FORENSIC AUDITS ON LIGHTWEIGHT IOT AND DIGITAL ARCHIVES
A new series of secure logging schemes that are referred to as Optimal Signatures for secure Logging (OSLO) are created. OSLO schemes are the first AS-based secure logging schemes that achieve small-constant tag and public key sizes with near-optimal signing and batch verification via various granularities. These features make them ideal for IoT-STaaS applications, wherein efficient signing and batch verification are critical for the resource-limited IoTs and cold storage servers, respectively.
H04L 9/32 - Arrangements for secret or secure communications; Network security protocols including means for verifying the identity or authority of a user of the system
52.
METHOD OF TREATING LONG-COVID INDUCED NEUROLOGIC DISEASES
A method of treating or preventing Alzheimer's disease or related dementias in patients previously infected with a respiratory virus such as SARS CoV2 is presented. Brain gene expression profiles of severe COVID-19 patients show increased expression of several innate immune response genes and genes implicated in Alzheimer's disease pathogenesis. The gene expression signature includes genes involved in inflammation, protein folding/trafficking, complement activation, calcium homeostasis, and amyloid/tau processing. The gene expression signature is correlated with tau pathology, α-synuclein, and demyelination with neuroinflammation being increased in old versus young CoV-2 infected mice.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
53.
SYSTEMS AND METHODS FOR ENERGY EFFICIENT AND USEFUL BLOCKCHAIN PROOF OF WORK
The disclosure provides systems and methods for an improved Proof of Work (PoW) technique that enforces the creation of cryptographic tokens while solving the PoW puzzle. The systems and methods disclosed herein more efficiently utilize the high computational and energy consumption in attempts to solve PoW puzzles, by combining the computations necessary for several types of cryptographic functions (e.g., public-key cryptographic methods). For example, systems and methods disclosed herein may reuse pre-computed commitments, while still preserving the traditional and accepted PoW protocols.
H04L 9/32 - Arrangements for secret or secure communications; Network security protocols including means for verifying the identity or authority of a user of the system
H04L 9/14 - Arrangements for secret or secure communications; Network security protocols using a plurality of keys or algorithms
H04L 9/00 - Arrangements for secret or secure communications; Network security protocols
54.
SIMULTANEOUS POLARIZED LIGHT VIEWING/IMAGING THROUGH A SPLIT POLARIZER
Described herein relates to a system and method of filtering a polarized light through at least a polarization orientation for simultaneous viewing. The polarizing light filter apparatus may comprise at least one light source and/or a split polarizer configured to provide the polarization orientation of incident light. Light source may be configured to emit the incident light toward a structure, such that the incident light may be reflected off the structure through the split polarizing comprising a first polarization orientation (e.g., parallel) and/or a second polarizing orientation (e.g., cross). The reflected light may travel through the split polarizer, providing a simultaneous view of the first polarization orientation and/or the second polarization orientation, in real-time. Moreover, the simultaneous view of the polarized light may allow for a more detailed visual experience as well as optimize the ability to determine which orientation of light best illuminates a feature of interest.
A method for achieving a target joint preload includes identifying a thread pitch of a first fastener element used to secure two components together. The first fastener element is passed through the two components and a second fastener element is threaded onto the first fastener element. A tightening torque is applied to the second fastener element, which is measured as the trial tightening torque. A loosening torque is applied to the second fastener element, which is measured as the trial removal torque. A required tightening torque that is required to be applied to the second fastener element to achieve the target joint preload is calculated using only the thread pitch, the trial tightening torque, the trial removal torque, and the target joint preload.
G01L 5/24 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes for determining value of torque or twisting moment for tightening a nut or other member which is similarly stressed
B25B 23/147 - Arrangement of torque limiters or torque indicators in wrenches or screwdrivers specially adapted for electrically operated wrenches or screwdrivers
56.
SMART THERMAL MANAGEMENT SYSTEM TO PREVENT THERMAL RUNAWAY IN RECHARGEABLE BATTERIES
A battery management system comprises: a circuit path electrically coupling a battery and a load; a backup storage device; a first switch connecting the battery and the backup storage device; a second switch connecting the backup storage device and the load; a sensor for measuring a temperature of the battery; and a controller in electrical communication with the first switch, the second switch, and the sensor. The controller executes a program to: (i) activate the first switch to connect the battery and the backup storage device for charging the backup storage device for a charging period of time with power provided by the battery based on the temperature of the battery meeting a threshold, and (ii) activate the second switch to connect the backup storage device and the load for providing power to the load from the backup storage device after the charging period of time has expired.
H01M 10/48 - Accumulators combined with arrangements for measuring, testing or indicating the condition of cells, e.g. the level or density of the electrolyte
H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
H01M 10/651 - Means for temperature control structurally associated with the cells characterised by parameters specified by a numeric value or mathematical formula, e.g. ratios, sizes or concentrations
57.
N-Myc-Interactor protein as a marker for chronic lung disease and uses thereof
A method of predicting the development of chronic lung allograft dysfunction (CLAD) in lung transplant patients using N-myc-interactor (NMI) as a biomarker and associated treatment thereof is presented. Also presented is a method of reducing the risk of CLAD by administering a therapeutic agent capable of increasing NMI in the patient. NMI is a critical regulator of epithelial-to-mesenchymal transition (EMT) and an important precursor to development of CLAD. NMI expression is reduced in CLAD patients and can be used as an early diagnostic biomarker to predict the development of CLAD. NMI can also be used as a drug target for a therapeutic to increase expression of NMI and treat chronic lung disease such as CLAD. Therapeutics comprising NMI protein or NMI gene can be used as potential treatments for chronic lung diseases such as CLAD.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61K 9/00 - Medicinal preparations characterised by special physical form
A novel method for preventing Alu-mediated interferon related pathologies and excessive Alu-mediated interferon production and inflammatory response is presented. Administration of LIN28B was found to reduce IFN production by binding to Alu RTs and shielding them from binding to dsRNA sensors thus preventing Alu-mediated IFN related pathologies such as viral infections.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
59.
Systems and methods for generating tactile 3D maps
A method for generating three dimensional indicators for the visually impaired. The method includes selecting one or more pre-designed symbols from a plurality of pre-designed symbols. The pre-designed symbols represent standard building layout features and are sized to be readable via a physical touch. The method further includes inserting the one or more selected symbols into a two dimensional digital layout, and generating one or more of an orientation object and a legend object into the two dimensional digital layout. The method further includes converting the two dimensional digital layout into a three dimensional digital model, and generating an output file including the three dimensional model in a format compatible with a three dimensional printing device.
A method for generating a predictive safety assessment of at least one existing facility and at least one proposed facility includes obtaining data about an existing facility and each proposed facility, receiving user input data regarding local conditions for the existing facility and each proposed facility, determining a predicted crash frequency for the existing facility and each proposed facility based at least on a set of Safety Performance Function (SPFs) associated with a facility type for the existing facility and each proposed facility respectively, determining a conversion factor for each proposed facility based on the predicted crash frequency of the existing facility and the predicted crash frequency of each proposed facility, determining a crash severity distribution by crash types, determining an impact of local traffic volume for each proposed facility, and generating a user interface to render a graphical representation of at least each conversion factor for each proposed facility.
A method analyzing benefits and cost for a roadway improvement project includes obtaining definitions of a plurality of emphasis areas associated with a highway safety plan, and obtaining crash data associated with each of the plurality of emphasis areas. The crash data can include a plurality of crashes, a location of each crash, functional class associated with each crash, and injury levels associated with each crash. The method further includes obtaining countermeasure and Crash Modification Factor (CMF) data associated with each emphasis area, obtaining spatial assignments for each crash, determining a frequency of crashes for at least one injury level for each emphasis area, determining a plurality of costs associated with each countermeasure in the countermeasure and CMF data, a benefit cost ratio for each countermeasure in the countermeasure and CMF data associated with the emphasis area, and generating a first user interface configured to render a table or a visualization based at least on at least one emphasis area, the set of countermeasures, and the benefit cost ratio associated with the at least one countermeasure.
G06Q 10/0637 - Strategic management or analysis, e.g. setting a goal or target of an organisation; Planning actions based on goals; Analysis or evaluation of effectiveness of goals
A system and method for assessing a supply chain for a perishable product. In various embodiments, the present invention provides a quality code for a perishable product which encodes a cut-to-cool time, transportation quality and accumulated shelf-life loss into a compact, modular, and simple to read format. The system and method also provide feedback to address any differences between the quality code and one or more observed qualities of the perishable product at a destination.
Described herein relates to novel methods for determining susceptibility for infection and/or disease (e.g., pregnancy complication and/or cancer), and/or predicting severity of infection and/or disease by measuring circulating Alu RNA by RT-PCR (e.g., circulating blood, serum, and/or plasma). Additionally, described herein relates to novel methods of treating infection and/or disease (e.g., pregnancy complication and/or cancer), via increasing immune response, optimizing vaccine delivery, via administering at least one Alu RNA into the subject.
Disclosed are methods of forming a method for forming spectrally selective nanoparticles, the method comprising: heating a growth solution comprising a zinc salt precursor, zinc oxide seed particles, and one or more dopants in a non-pressurized hydrothermal reactor to a first temperature under agitative conditions for a reaction period; cooling the reactor to a second temperature less than the first temperature for a cooling period to form a precipitate of recrystallized doped zinc oxide nanoparticles dispersed in a suspension; and separating and collecting the recrystallized nanoparticles from the suspension, wherein the collected nanoparticles exhibit a spectral selectivity in the atmospheric window.
Disclosed are methods of forming a method for forming spectrally selective nanoparticles, the method comprising: heating a growth solution comprising a zinc salt precursor, zinc oxide seed particles, and one or more dopants in a non-pressurized hydrothermal reactor to a first temperature under agitative conditions for a reaction period; cooling the reactor to a second temperature less than the first temperature for a cooling period to form a precipitate of recrystallized doped zinc oxide nanoparticles dispersed in a suspension; and separating and collecting the recrystallized nanoparticles from the suspension, wherein the collected nanoparticles exhibit a spectral selectivity in the atmospheric window.
Also disclosed herein are comprising a population of polycrystalline zinc oxide nanoparticles doped with one or more dopants, wherein the population of nanoparticles is spectrally selective in the atmospheric window.
Provided herein are systems and methods for automated identification of volumes of interest in volumetric brain images using artificial intelligence (AI) enhanced imaging to diagnose and treat acute stroke. The methods can include receiving image data of a brain having header data and voxel values that represent an interruption in blood supply of the brain when imaged, extracting the header data from the image data, populating an array of cells with the voxel values, applying a segmenting analysis to the array to generate a segmented array, applying a morphological neighborhood analysis to the segmented array to generate a features relationship array, where the features relationship array includes features of interest in the brain indicative of stroke, identifying three-dimensional (3D) connected volumes of interest in the features relationship array, and generating output, for display at a user device, indicating the identified 3D volumes of interest.
G06V 10/77 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]; Blind source separation
G06V 10/26 - Segmentation of patterns in the image field; Cutting or merging of image elements to establish the pattern region, e.g. clustering-based techniques; Detection of occlusion
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Mohapatra, Shyam S.
Mohapatra, Subhra
Abstract
The present invention pertains to a strategy of selectively targeting oncolytic virotherapy, using either naturally occurring or genetically modified viruses by packaging them in mesenchymal stem cells (MSCs). The present invention concerns MSCs, compositions comprising the MSCs, and methods of using the MSCs for treatment of cancer and for lysing or inducing apoptosis of cancer cells in vitro or in vivo.
A system configured to perform the DCS-type measurements with the use of low-coherence continuous-wave (CW) light source at levels of light intensities that are substantially lower and with pathlengths through the tissue that are substantially longer than those afforded by the use of conventional methods. The method includes utilizing the optical detection system to producing signals representing interference between the portion of CW light arriving through reference arm of interferometer and the sample CW light potion that has traversed the sample arm including different paths through the target tissue while switching between first and second of said different paths only by adjusting a delay in the delay line. The spatial resolution of different pathlengths of sample light through tissue is defined by coherence length of CW light.
In one embodiment, a phase change material is encapsulated by forming a phase change material pellet, coating the pellet with flexible material, heating the coated pellet to melt the phase change material, wherein the phase change materials expands and air within the pellet diffuses out through the flexible material, and cooling the coated pellet to solidify the phase change material.
C09K 5/06 - Materials undergoing a change of physical state when used the change of state being from liquid to solid or vice-versa
C09K 5/00 - Heat-transfer, heat-exchange or heat-storage materials, e.g. refrigerants; Materials for the production of heat or cold by chemical reactions other than by combustion
C23C 18/16 - Chemical coating by decomposition of either liquid compounds or solutions of the coating forming compounds, without leaving reaction products of surface material in the coating; Contact plating by reduction or substitution, i.e. electroless plating
F28F 21/06 - Constructions of heat-exchange apparatus characterised by the selection of particular materials of plastics material
F28D 20/02 - Heat storage plants or apparatus in general; Regenerative heat-exchange apparatus not covered by groups or using latent heat
A system and method for pain level recognition using an automated approach which incorporates a pain-affect dataset comprising bioVid pain and bioVid emotion datasets for the assessment of patient pain in clinical settings where patients often experience other affect states, such as anger and anxiety, in addition to pain.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G06V 40/16 - Human faces, e.g. facial parts, sketches or expressions
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
71.
SYSTEMS AND METHODS FOR TREATING A SACROILIAC JOINT
A method of treating a sacroiliac joint and/or a region proximate the sacroiliac joint includes distracting and/or stabilizing a recess between a sacral wall of a sacrum and an ilial wall of an ilium, cutting a surface of the ilial wall using a cutting device, and positioning an implant having a first planar wall and a second planar wall opposite the first planar wall into the recess, such that the first planar wall of the implant is in contact with an uncut surface of the sacral wall, and the second planar wall is in contact with the cut surface of the ilial wall. The implant can be formed as a wedge-shape, a double-wedge shape, or a cuboid shape.
A fluid flow conditioning apparatus having self-adjusting tab members that reduce flow losses within a conduit. A plurality of tabular members is affixed to an insertion plate-type flow conditioner. Tabular members are cojoined in pairs at their leading edges. When the cojoined pair of the first tabular member and the second tabular member are placed into a fluid flow, an angle between the first tabular member and the second tabular member is configured to decrease in response to static and dynamic pressure exerted onto the outer surfaces of the tabular members by the fluid flow. The tabular members may be made of a hyperplastic material configured to undergo an elastic deformation and exhibit flapping due to the dynamic pressure of the fluid flow. Tabular members maybe cojoined by a hinge configured to partially close in response to pressure exerted by the fluid flow, decreasing the angle between the tabular members.
The present disclosure describes compositions for reducing hypergranulation tissue and methods of their use. The compositions comprise bacitracin, polymyxin b, and triamcinolone.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 9/00 - Medicinal preparations characterised by special physical form
Disclosed are various embodiments for computing 2-body statistics on graphics processing units (GPUs). Various types of two-body statistics (2-BS) are regarded as essential components of data analysis in many scientific and computing domains. However, the quadratic complexity of these computations hinders timely processing of data. According, various embodiments of the present disclosure involve parallel algorithms for 2-BS computation on Graphics Processing Units (GPUs). Although the typical 2-BS problems can be summarized into a straightforward parallel computing pattern, traditional wisdom from (general) parallel computing often falls short in delivering the best possible performance. Therefore, various embodiments of the present disclosure involve techniques to decompose 2-BS problems and methods for effective use of computing resources on GPUs. We also develop analytical models that guide users towards the appropriate parameters of a GPU program. Although 2-BS problems share the same core computations, each 2-BS problem however carries its own characteristics that calls for different strategies in code optimization. Accordingly, various embodiments of the present disclosure involve a software framework that automatically generates high-performance GPU code based on a few parameters and short primer code input.
In one embodiment, a system for monitoring heart rate variability including an electrode configured to be placed against a user’s chest and generate heart beat data and a data collection and processing device that receives the heart beat data from the electrode, the data collection and processing device being configured to execute a heart rate variability program configured to continually determine the user’s heart rate variability in real time based upon the heart beat data and to determine whether or not the user is in physiological distress based upon the determined heart rate variability.
The present disclosure relates to methods of detecting, treating, and/or preventing the progression of diseases, such as Alzheimer's disease using a complementarity scoring method.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
77.
COMPOSITIONS COMPRISING CelTOS IMMUNOGENS AND ANTIBODIES AND METHOD OF USE THEREOF
The present disclosure provides immunogenic compositions and methods for vaccination with a CelTOS immunogen. The immunogenic composition comprises Babesia, Theileria or Cytauxzoon CelTOS. The immunogenic composition may also comprise CelTOS with structural changes that affect immune recognition.
Perovskite oxides and catalysts containing the perovskite oxides are provided for the thermochemical conversion of carbon dioxide to carbon monoxide. The perovskite oxides can exhibit large carbon monoxide production rates and/or low carbon monoxide production onset temperatures as compared to existing materials. Reactors are provided containing the perovskite oxides and catalysts, as well as methods of use thereof for the thermochemical conversion of carbon dioxide to carbon monoxide.
B01J 23/78 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with alkali- or alkaline earth metals or beryllium
B01J 23/83 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with rare earths or actinides
C01F 17/32 - Compounds containing rare earth metals and at least one element other than a rare earth metal, oxygen or hydrogen, e.g. La4S3Br6 oxide or hydroxide being the only anion, e.g. NaCeO2 or MgxCayEuO
79.
DEVICE FOR TARGETED FEATURE-SPECIFIC SENSORY THERAPY
A device and method that supplements sensory input, thereby providing a supplemented sensory environment, to induce plasticity within the central nervous system that effectively overcomes sensory-neural processing deficits or strengthens specific sensory-neural abilities. In one implementation, ear-level hearing devices are used to deliver therapeutic sound with specific acoustic features that serve as archetypes of stimulus features for which sensory-neural processing is compromised by a sensory-neural deficit.
A novel electrode and associated method of manufacturing said novel electrode comprising a porous structure having absorbed polystyrene sulfonate (PSS), a self-assembled polypyrole (PPy) layer adjacent to the PSS absorbed porous structure, a self-assembled polyaniline (PANI) layer adjacent to the PPy layer, an electrochemically deposited PANI layer adjacent to the PPy layer and an electrochemically deposited PANI-dichalcogenide layer adjacent to the electrochemically deposited PANI layer. A supercapacitor and associated method of manufacturing a supercapacitor comprising a first novel electrode and a second novel electrode separated by a polyvinyl gel and a porous separator.
Disclosed herein is a method to isolate and cultivate the lung microbiome obtained from bronchoalveolar lavage. The disclosed method involves lung microbiome culturomics based on three different media for both aerobic and fastidious anaerobic bacteria. The disclosed method allows for amplification of the lung microbiome, which can be used, for example, for subsequent testing of antibiotic sensitivity, drug resistance, or for lung microbiome transplantation.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
84.
Method of selecting an optimal propagated base signal using artificial neural networks
A system and method of propagating signal links by using artificial neural networks and a relay link selection protocol to predict an optimal signal path. The artificial neural networks used in the method classify training and testing datasets into sufficient signal strengths and insufficient signal strengths, such that paths are evaluated for predicted propagation links, such that the strongest propagation link can be selected. Specifically, a multilayer perceptron method is used to identify and characterize new link candidates using the path loss parameter or the received signal strength, such that optimal links can be selected and updated.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 31/401 - Proline; Derivatives thereof, e.g. captopril
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
86.
SYSTEM AND METHOD FOR ATTENTIONAL MULTIMODAL PAIN ESTIMATION
A computer-based system and method for generating a pain score of a subject using one or more sensory signals extracted from an AV signal of the subject. The AV signal may comprise one or more sensory signals including a face sensory signal, a body sensory signal and an audio sensory and wherein one or more of the sensory signals is missing from the AV signal.
The disclosure provides an article comprising a substrate having a surface including (i) a matrix of an optically transparent polymeric material having a first surface functionality, and (ii) at least one plasma-treated surface region comprising a portion of the surface, wherein each surface region comprises a second surface functionality, and wherein the first surface functionality and the second surface functionality are different The disclosure also provides a method for forming an article, the method comprising: (a) providing a substrate having a surface including an optically transparent polymeric material, (b) contacting the surface with a first plasma to create at least one plasma-treated surface region comprising a portion of the surface, each plasma-treated surface region having a first surface functionality, and (c) contacting each plasma-treated surface region with a second plasma to create a second surface functionality.
A system and methods for operating a multi-robot system (MRS) are disclosed. In some aspects, each robot of the MRS can: determine a local system regret state belief based on local evidence obtained by the robot itself and social evidence provided by other robots in a social community, determine a local system drift state belief based on the local system regret state belief, determine a next action based on the based on the local system regret state belief and the local system drift state belief, and execute the next action. Local system regret state belief is generally an estimation of a system regret state for the MRS. Local system drift state belief is generally an estimate of a system drift state for the MRS.
Provided are methods of modulating inflammation, modulating cancer cell trafficking, modulating chemokine receptor heteromerization, or modulating activity of a chemokine receptor by administering to a subject in need thereof a therapeutically effective amount of a modulator of an adrenergic receptor and/or an arginine vasopressin receptor. Chemokine receptor modulators can also be administered to the subject. Additionally, disclosed are compositions comprising a modulator of an adrenergic receptor and/or an arginine vasopressin receptor, and at least one cytokine receptor modulator.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
90.
Piezeoelectric-based asphalt layer for energy harvesting roadway
An energy harvesting roadway that includes a plurality of road segments and a power storage device electrically coupled to the plurality of road segments. Each of the plurality of road segments can include a surface asphalt layer, a first conductive asphalt layer located under the surface asphalt layer, a piezoelectric-based asphalt layer located between the first conductive layer and a second conductive layer located above a base asphalt layer. The piezoelectric-based asphalt layer can include a plurality of rigid piezoelectric elements and an insulating filler.
E01C 1/00 - Design or layout of roads, e.g. for noise abatement, for gas absorption
H02N 2/18 - Electric machines in general using piezoelectric effect, electrostriction or magnetostriction producing electrical output from mechanical input, e.g. generators
91.
Content masking attacks against information-based services and defenses thereto
The embodiments present a new class of content masking defenses against the Portable Document Format (PDF) standard. The defenses can identify attacks that cause documents to appear different than the underlying content extracted from the documents. A content masking defense method can include identifying a content masking attack by scanning a document file to extract a character code of a character appearing in the file. Next, the character is rendered based on a font that is embedded in the document file. Optical character recognition can be performed on the rendering, and a content masking attack can be identified based on a comparison of a result of the optical character recognition against the character code of the character.
Systems and methods for efficient cryptographic signing in heterogeneous systems that include IoT or other resource-limited devices. A signer which is the resource-limited device is not expected to generate, store and/or communicate expensive commitment values and/or public keys. A secure hardware platform serves as PUblic nonce-Commitment-Key Oracle (PUCKO) that computes and transmits commitments (e.g., one-time public key keys, ephemeral algebraic commitments) on behalf of the signer(s) to verifiers (or other signers in distributed signatures).
H04L 9/32 - Arrangements for secret or secure communications; Network security protocols including means for verifying the identity or authority of a user of the system
A novel method of treating cancer is presented. API transcriptionally regulates SHIP-1 expression via the suppression of miRNA-155, impacting anti-tumor immune responses in the bone marrow (BM) and TME of mice with PC. The inventors discovered that API reduced miRNA-155 in the PC milieu, which induced SHIP-1 expression. This promoted the restoration of myelopoiesis and increased anti-tumor immune responses in the TME of heterotopic, orthotopic and transgenic SHIP-1 knockout preclinical mouse models of PC. The results suggest that manipulating SHIP-1 through miR-155 can assist in augmenting anti-tumor immune responses and aid in the therapeutic intervention of PC. Further, administration of both API and an miR-155 inhibitor were found to act synergistically to treat pancreatic cancer.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
94.
Nicotinic receptor antagonists and pioglitazone as therapeutic agents for Covid-19
A method of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), otherwise known as COVID-19, infection by administering nicotinic receptor antagonists and/or PPAR-γ agonists is presented. A combination of mecamylamine, or an isomer thereof, and pioglitazone synergistically reduces replication of SARS-CoV-2 in virus-infected cells and also synergistically reduces inflammatory cytokines such as IL-6, IL-β, and TNFα, which have been associated with SARS-CoV-2 infection.
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A novel method of treating diseases characterized by high PAI-1 is presented. Administering a composition comprising a therapeutically effective amount of genistein was found to inhibit PAI-1 promotor activity and decrease PAI-1 levels to treat diseases such as asthma, which exhibit increased PAI-1 levels. Genotyping the patient can be performed prior to administration to detect a 4G/5G polymorphism as patients having a 4G genotype have better response to the genistein treatment. The composition may be comprised of a therapeutically effective amount of genistein derived naturally from soybeans or synthetically produced and optionally present in nanoparticle form.
C07D 311/08 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
96.
CLASSIFICATION OF GLOBAL CELL PROLIFERATION BASED ON DEEP LEARNING
A method for automatic classification is disclosed. The method includes: training a deep learning model with a first set of a plurality of local images of first cells of a first tissue with a low magnification equal to or less than 40x; inputting a runtime image including second cells of a second tissue corresponding to the first tissue with the low magnification equal to less than 40x in the deep learning model; and automatically classifying a total number of the runtime cells in the runtime image as a proliferation level based on an output of the trained deep learning model. Other aspects, embodiments, and features are also claimed and described.
Sensors and related methods for detecting chemicals, gases and molecules using a plurality of electrodes, a liquid mucus based electrolyte and a separator to hold the liquid electrolyte and wet the surface of the first electrode and wet the surface of the second electrode with the liquid electrolyte. One or more electrodes may include a metallophthalocyanine or a metalloporphyrin or a derivative thereof or an electrode may be in electrical contact with a metallophthalocyanine or a metalloporphyrin.
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (USA)
Inventor
Paul, Rahul
Goldgof, Dmitry
Hall, Lawrence
Schabath, Matthew
Gillies, Robert
Abstract
The present disclosure describes a multi-initialization ensemble-based defense strategy against an adversarial attack. In one embodiment, an exemplary method includes training a plurality of conventional neural networks (CNNs) with a training set of images, wherein the images include original images and images modified by an adversarial attack; after training of the plurality of conventional neural networks, providing an input image to the plurality of conventional neural networks, wherein the input image has been modified by an adversarial attack; receiving a probability output for the input image from each of the plurality of conventional neural networks; producing an ensemble probability output for the input image by combining the probability outputs from each of the plurality of conventional neural networks; and labeling the input image as belonging to one of the one or more categories based on the ensemble probability output.
G06F 18/2415 - Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches based on parametric or probabilistic models, e.g. based on likelihood ratio or false acceptance rate versus a false rejection rate
Compositions and methods for inducing weight loss, fat loss, maintaining weight or fat loss, suppressing appetite, reducing calorie intake, reducing weight gain, decreasing feed efficiency, increasing metabolic inefficiency, increasing energy expenditure, increasing thermogenesis and/or resetting metabolic set are disclosed. The compositions have a therapeutically effective amount of a ketogenic supplement, e.g., a ketone diesters, such as R,S 1,3-butanediol diacetoacetate. Compositions of one or more beta-hydroxy butyrate, beta-hydroxybutyrate salt, and medium chain triglycerides are also disclosed.
Methods and systems for patient-specific post-surgery mortality prediction are disclosed. The methods and systems include: receiving a plurality of pre-operative factor indications for a patient; obtaining a first trained machine learning model and an interpretable model; applying the plurality of pre-operative factor indications to the first trained machine learning model to obtain a plurality of confidence values corresponding to the plurality of pre-operative factor indications; applying the plurality of confidence values to the interpretable model to obtain a plurality of interpretation indications, the plurality of interpretation indications corresponding to a subset of the plurality of pre-operative factor indications, the plurality of interpretation indications most contributing to mortality of the patient, the plurality of interpretation indications being specific to the patient; and outputting a survival probability of the patient based on the plurality of interpretation indications. Other aspects, embodiments, and features are also claimed and described.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G06N 3/0442 - Recurrent networks, e.g. Hopfield networks characterised by memory or gating, e.g. long short-term memory [LSTM] or gated recurrent units [GRU]
